Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Adherium Ltd. ( (AU:ADR) ).
Adherium Limited has appointed Ms Victoria Durrans as an alternate director to board member Mr Jeremy Curcock Cook, effective immediately, strengthening its governance with additional expertise from its key investor base. Durrans, a partner at BioScience Managers with experience in building high-growth technology companies and shaping boards and management teams, is expected to support Adherium’s growth strategy as it expands its digital respiratory management platform in global markets.
Her background spans fund formation, investment sourcing and execution, value creation in portfolio companies and operational oversight, aligning closely with Adherium’s ambitions to scale its Hailie Smartinhaler business. The appointment underscores continued investor engagement in the company’s strategic direction and is likely to enhance board capabilities in driving execution and long-term value creation for stakeholders.
The most recent analyst rating on (AU:ADR) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Adherium Ltd. stock, see the AU:ADR Stock Forecast page.
More about Adherium Ltd.
Adherium Limited is an Australian digital health company and global leader in connected respiratory medical devices, best known for its FDA-cleared Hailie Smartinhaler platform. The company provides integrated remote monitoring solutions for clinicians, healthcare providers and patients, offering data capture and sharing via apps, APIs and sensor-enabled inhaler devices to improve respiratory disease management and support reimbursement pathways.
Technical Sentiment Signal: Sell
Current Market Cap: A$13.97M
Learn more about ADR stock on TipRanks’ Stock Analysis page.